A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was designed to determine the maximum tolerated dose of Gl147211 as a 72-h infusion and to describe its pharmacokinetics and pharmacodynamics on this schedule. In a single-arm, risi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, L., Kunka, R., DeMaria, D., Cassidy, J., Alden, M., Beranek, P., Kaye, S., Littlefield, D., Reilly, D., Depee, S., Wissel, P., Twelves, C., O'Dwyer, P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063170/
https://www.ncbi.nlm.nih.gov/pubmed/9823974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063170/
https://www.ncbi.nlm.nih.gov/pubmed/9823974

Ejemplares similares